Economic Evaluation in Genomic and Precision Medicine

In: Translational and Applied Genomics Series

Abstract

Intro -- Economic Evaluation in Genomic and Precision Medicine -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1: Introduction to economic evaluation in health sciences -- 1.1. Introduction -- 1.2. Key economic concepts and terminology used in health economics -- 1.2.1. Budget constraints and demand -- 1.2.2. Utility -- 1.2.3. Indifference curves -- 1.2.4. Social welfare -- 1.3. Economic evaluation -- 1.3.1. Rationale for economic evaluation -- 1.3.2. Types of economic evaluation -- 1.3.2.1. The extra-welfarist approach to economic evaluation -- 1.3.2.2. The welfarist approach to economic evaluation -- 1.3.2.3. Welfarism versus extra-welfarism: Which approach should be used? -- 1.4. Concluding remarks -- References -- Chapter 2: Foundations of pharmacogenomics and personalized medicine -- 2.1. Introduction -- 2.2. Implementing pharmacogenomics into clinical care -- 2.2.1. Pharmacogenomics for cancer therapeutics -- 2.2.2. Pharmacogenomics for drug treatment of cardiovascular diseases -- 2.2.3. Pharmacogenomics for psychiatric diseases -- 2.3. Electronic tools for translating genomic findings into a clinically meaningful format -- 2.4. Assessing the ethical, societal, and financial aspects of personalized medicine -- 2.4.1. Ethical and legal issues -- 2.4.2. Raising genomics awareness among healthcare professionals and the general public -- 2.4.3. Economic evaluation of personalized medicine interventions -- 2.5. Large-scale personalized medicine implementation efforts worldwide -- 2.6. Conclusions and future perspectives -- Acknowledgments -- References -- Chapter 3: Economic evaluation of genome-guided treatment in oncology -- 3.1. Introduction -- 3.2. Methodological challenges -- 3.3. The inseparability of test and treatment -- 3.4. Value of testing -- 3.5. Cost-effectiveness comparator -- 3.6. Pricing and reimbursement.